TUSC2 gene therapy in KRASG12C mutant NSCLC overcomes acquired resistance to sotorasib

被引：0
|
作者：
Meraz, I. [1 ]
Majidi, M. [1 ]
Gao, L. [1 ]
Ren, C. [1 ]
Wu, S. [1 ]
Song, R. [1 ]
Meng, F. [1 ]
Xu, Y. [1 ]
Wang, Q. [2 ]
Xi, Y. [2 ]
Wang, J. [2 ]
Jung, S. Y. [3 ]
Shpall, E. [4 ]
Roth, J. A. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Thorac & Cardiovasc Surg, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Bioinformat & Computat Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Biochem, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat, Houston, TX 77030 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB372
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [21] RMC-4630 and sotorasib for advanced KRASG12C NSCLC after failure of prior standard therapies: A phase II trial
    Johnson, M. L.
    Langdon, R.
    Ellison, D.
    Spira, A.
    Amin, H.
    Castine, M.
    Daniel, D. B.
    Sohoni, S.
    Chen, Y-C.
    Hayes, J.
    Mu, Y.
    Masciari, S.
    Wang, X.
    Toya, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S66 - S67
  • [22] Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells
    Lee, Chaeyoung
    Yi, Jawoon
    Park, Jihwan
    Ahn, Byungyong
    Won, Young-Wook
    Jeon, Jiheung
    Lee, Byung Ju
    Cho, Wha Ja
    Park, Jeong Woo
    CELL DEATH & DISEASE, 2024, 15 (01)
  • [23] Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells
    Chaeyoung Lee
    Jawoon Yi
    Jihwan Park
    Byungyong Ahn
    Young-Wook Won
    JiHeung Jeon
    Byung Ju Lee
    Wha Ja Cho
    Jeong Woo Park
    Cell Death & Disease, 15
  • [24] Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumour immunity
    Anastasiou, P.
    Boumelha, J.
    Mugarza, E.
    Rana, S.
    Moore, C.
    Arcas, M. Molina
    Downward, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S62 - S62
  • [25] Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor immunity
    Anastasiou, Panayiotis
    Mugarza, Edurne
    Boumelha, Jesse
    Rana, Sareena
    Moore, Christopher
    Molina-Arcas, Miriam
    Downward, Julian
    CANCER RESEARCH, 2022, 82 (12)
  • [26] Aurora A kinase inhibition with VIC-1911 overcomes intrinsic and acquired resistance to KRASG12C inhibition in KRAS(G12C)-mutated lung cancer
    Lee, Jong Woo
    Kim, Sundong
    Yang, Cindy
    Burtness, Barbara
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [27] Reflections on drug resistance to KRASG12C inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment
    Han, ZhaoYong
    Zhou, Ding
    Wang, JiaMan
    Jiang, Bruce
    Liu, XiYu
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (01):
  • [28] HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2
    Ho, Cassandra S. L.
    Tuens, Alicia, I
    Schildhaus, Hans-Ulrich
    Wiesweg, Marcel
    Gruener, Barbara M.
    Hegedus, Balazs
    Schuler, Martin
    Schramm, Alexander
    Oeck, Sebastian
    EUROPEAN JOURNAL OF CANCER, 2021, 159 : 16 - 23
  • [29] The gRAss Is Greener: Potential new Therapies in Lung cancer with Acquired Resistance to KRAsG12c Inhibitors
    Pinnelli, Marika
    Trusolino, Livio
    CANCER DISCOVERY, 2021, 11 (08) : 1874 - 1876
  • [30] Detection of KRAS amplification on extrachromosomal DNA (ecDNA) upon acquired resistance to KRASG12C inhibitors
    Hansen, Ryan J.
    Horton, Steven
    Wiese, Julie
    Bibay, BellJohn
    Mora-Blanco, E. Lorena
    Nguyen, Nam-Phuong
    Engstrom, Lars D.
    Briere, David M.
    Calinisan, Andres
    Olson, Peter
    Awad, Mark M.
    Aguirre, Andrew J.
    Christiansen, Jason
    Hassig, Christian
    Kasibhatla, Shailaja
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
12345